期刊
ONCOGENE
卷 29, 期 32, 页码 4576-4587出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/onc.2010.208
关键词
anticancer drug; p53; K-Ras; Snail; pancreatic cancer
资金
- national cancer center of Korea [0920250]
- Pusan National University [PNU-2008-101-20080596000]
- Ministry of Education, Science and Technology [2009-0093815]
- Korea Health Promotion Institute [0920250] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
p53 is frequently mutated by genetic alternation or suppressed by various kinds of cellular signaling pathways in human cancers. Recently, we have revealed that p53 is suppressed and eliminated from cells by direct binding with oncogenic K-Ras-induced Snail. On the basis of the fact, we generated specific inhibitors against p53-Snail binding (GN25 and GN29). These chemicals can induce p53 expression and functions in K-Ras-mutated cells. However, it does not show cytotoxic effect on normal cells or K-Raswild- type cells. Moreover, GN25 can selectively activate wild-type p53 in p53(WT/MT) cancer cells. But single allelic mt p53 containing cell line, Panc-1, does not respond to our chemical. In vivo xenograft test also supports the antitumor effect of GN25 in K-Ras-mutated cell lines. These results suggest that our compounds are strong candidate for anticancer drug against K-Ras-initiated human cancers including pancreatic and lung cancers. Oncogene (2010) 29, 4576-4587; doi: 10.1038/onc.2010.208; published online 7 June 2010
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据